Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation
Blood · 2023
DOI: 10.1182/blood.2022016052 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Feiyan Mo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Graft vs Host Disease, Leukemia, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIAID NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Acute graft-versus-host disease (aGVHD) limits the therapeutic benefit of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and requires immunosuppressive prophylaxis that compromises antitumor and antipathogen immunity. OX40 is a costimulatory receptor upregulated on circulating T cells in aGVHD and plays a central role in driving the expansion of alloreactive T cells. Here, we show that OX40 is also upregulated on T cells infiltrating GVHD target organs in a rhesus macaque model, supporting the hypothesis that targeted ablation of OX40+ T cells will mitigate GVHD pathogenesis. We thus created an OX40-specific cytotoxic receptor that, when expressed on human T cells, enables selective elimination of OX40+ T cells. Because OX40 is primarily upregulated on CD4+ T cells upon activation, engineered OX40-specific T cells mediated potent cytotoxicity against activated CD4+ T cells and suppressed alloreactive T-cell expansion in a mixed lymphocyte reaction model. OX40 targeting did not inhibit antiviral activity of memory T cells specific to Epstein-Barr virus, cytomegalovirus, and adenoviral antigens. Systemic administration of OX40-targeting T cells fully protected mice from fatal xenogeneic GVHD mediated by human peripheral blood mononuclear cells. Furthermore, combining OX40 targeting with a leukemia-specific chimeric antigen receptor in a single T cell product provides simultaneous protection against leukemia and aGVHD in a mouse xenograft model of residual disease posttransplant. These results underscore the central role of OX40+ T cells in mediating aGVHD pathogenesis and support the feasibility of a bifunctional engineered T-cell product derived from the stem cell donor to suppress both disease relapse and aGVHD following allo-HSCT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX.
- Graduate Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX.
- Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA.
- Department of Pediatrics, Harvard Medical School, Boston, MA.
- Graduate Program in Immunology and Microbiology, Baylor College of Medicine, Houston, TX.
- Department of Neuroscience, Baylor College of Medicine, Houston, TX.
ORCID-Profile: Feiyan Mo, Norihiro Watanabe, Kayleigh I Omdahl, Phillip M Burkhardt, Xiaoyun Ding, Helen E Heslop, Victor Tkachev, Maksim Mamonkin
Förderung
- NHLBI NIH HHS
- NIAID NIH HHS
- NCI NIH HHS
Zitieren
APA
Mo, F., Watanabe, N., Omdahl, K. I., Burkhardt, P. M., Ding, X., Hayase, E., Panoskaltsis-Mortari, A., Jenq, R. R., Heslop, H. E., Kean, L. S., Brenner, M. K., Tkachev, V., & Mamonkin, M. (2023). Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood. https://doi.org/10.1182/blood.2022016052
Vancouver
Mo F, Watanabe N, Omdahl KI, Burkhardt PM, Ding X, Hayase E, et al. Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood. 2023. doi:10.1182/blood.2022016052
BibTeX
@article{Mo2023,
author = {Mo, Feiyan and Watanabe, Norihiro and Omdahl, Kayleigh I and Burkhardt, Phillip M and Ding, Xiaoyun and Hayase, Eiko and Panoskaltsis-Mortari, Angela and Jenq, Robert R and Heslop, Helen E and Kean, Leslie S and Brenner, Malcolm K and Tkachev, Victor and Mamonkin, Maksim},
title = {Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2022016052}
}
EUVIMED